'Good health' as a barrier and facilitator to ART initiation: a qualitative study in the era of test-and-treat in Mozambique

Magaco, A., Dovel, K., Cataldo, F., Nhassengo, P., Hoffman, R., Nerua, L., Tique, J., Saide, M., Couto, A., Mbofana, F., Gudo, E., Cuco, R. M. and Chicumbe, S.

HIV test-and-treat programmes are being implemented throughout sub-Saharan Africa, enrolling HIV-positive clients into antiretroviral treatment (ART) immediately after diagnosis, regardless of clinical stage or CD4 count. This study conducted in Mozambique examined what influenced clients who tested HIV-positive in the context of test-and-treat to make ART initiation decisions. Eighty in-depth interviews with HIV-positive clients and nine focus group discussions with health care workers were completed across 10 health facilities. 'Good health' acted simultaneously as a barrier and facilitator; clients in good health often found a positive HIV diagnosis hard to cope with since HIV was traditionally associated with ill health. Concerns about ART side effects, fear of inadvertent HIV status disclosure and discrimination, limited privacy at health facilities and long waiting times were also barriers to initiation. In contrast, being in good health also acted as a motivator to start treatment so as to remain healthy, maintain responsibilities such as work and caring for dependents and avoid unwanted disclosure. Study findings offer an in-depth understanding of the complex dynamics between individual perceptions of 'being healthy' and its influence on ART initiation within the context of test-and-treat programme implementation.

April 12, 2019
Year of publication
2019
Resource types
Journal and research articles
Countries
Tags
test and treat, HIV-positive, antiretroviral therapy (ART), CD4 cell count, ART initiation

Similar Resources

Challenges to ensuring timely linkage to and retention in HIV care are well documented. Combination intervention strategies can be effective in improving the HIV care continuum.

Viral load (VL) monitoring for people on antiretroviral therapy (ART) is extremely challenging in resource-limited settings. We assessed the VL testing scale-up in six Médecins Sans Frontières supported health centres in Maputo, Mozambique, during 2014-15.

Increasing numbers of people living with HIV (PLHIV) in sub-Saharan Africa are experiencing failure of first-line antiretroviral therapy and transitioning onto second-line regimens. However, there is a dearth of research on their treatment experiences. We conducted in-depth interviews with 43 PLHIV…

Efavirenz has become one of the most commonly used antiretroviral agents worldwide and is a component of WHO's recommended first-line antiretroviral therapy regimen.

This supplement to Acta Paediatrica presents a series of meta-analyses and systematic literature reviews examining a variety of health effects potentially related to breastfeeding.

This issue of the Southern African HIV Clinicians Society's "HIV Nursing Matters" online magazine focuses on vulnerable populations, including TB in prisons and intimate partner violence in the context of HIV.

This issue of the Southern African HIV Clinicians Society's "HIV Nursing Matters" online magazine focuses on key populations.

Treatment with efavirenz has been associated with rare but severe liver complications among patients receiving antiretroviral therapy (ART) in South Africa.

Worldwide, approximately 35 million individuals are infected with HIV; about 25 million of these live in sub-Saharan Africa. WHO proposes using treatment as prevention (TasP) to eliminate HIV. Treatment suppresses viral load, decreasing the probability an individual transmits HIV.

Interruption of combination antiretroviral therapy (ART) in HIV-1-infected individuals leads to rapid viral rebound.